Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma
Combined large cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine carcinoma, accounting for approximately 10% of large cell neuroendocrine carcinoma (LCNEC). Mainly composed of coexisting adenocarcinoma components, with strong invasiveness and poor prognosis. The treatment regimen for C...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1449490/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850214980487479296 |
|---|---|
| author | Kai Kang Binfeng Li Sheng Wang Jianjian Wang Xinjun Liang |
| author_facet | Kai Kang Binfeng Li Sheng Wang Jianjian Wang Xinjun Liang |
| author_sort | Kai Kang |
| collection | DOAJ |
| description | Combined large cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine carcinoma, accounting for approximately 10% of large cell neuroendocrine carcinoma (LCNEC). Mainly composed of coexisting adenocarcinoma components, with strong invasiveness and poor prognosis. The treatment regimen for CLCNEC mainly refers to complete surgical resection as the first choice in the early stage, while patients with stage II or higher require adjuvant treatment. At present, research on CLCNEC is mostly small sample and retrospective, and there is no consensus on whether molecular typing and treatment should be carried out. There is considerable controversy over whether it should be managed as small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). Therefore, in order to solve the problem of confusion in the selection of treatment regimens for CLCNEC, while also considering the therapeutic effects, this article summarizes and analyzes previous studies, fully seeks evidence, and boldly proposes new therapeutic insights: the etoposide-platinum (EP) regimen serves as the basis for adjuvant therapy; In addition, SCLC/NSCLC-CLCNEC can be distinguished based on presence of RB1 and TP53 co-mutation, and targeted therapy or NSCLC type chemotherapy including platinum + gemcitabine or taxanes (NSCLC-GEM/TAX) can be used in combination or sequentially for NSCLC-CLCNEC. |
| format | Article |
| id | doaj-art-52c72d394cc14737bb315068dab193d0 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-52c72d394cc14737bb315068dab193d02025-08-20T02:08:45ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-10-011410.3389/fonc.2024.14494901449490Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinomaKai Kang0Binfeng Li1Sheng Wang2Jianjian Wang3Xinjun Liang4Thoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaThoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaThoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaThoracic Surgery, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaDepartment of Abdominal Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, ChinaCombined large cell neuroendocrine carcinoma (CLCNEC) is a rare neuroendocrine carcinoma, accounting for approximately 10% of large cell neuroendocrine carcinoma (LCNEC). Mainly composed of coexisting adenocarcinoma components, with strong invasiveness and poor prognosis. The treatment regimen for CLCNEC mainly refers to complete surgical resection as the first choice in the early stage, while patients with stage II or higher require adjuvant treatment. At present, research on CLCNEC is mostly small sample and retrospective, and there is no consensus on whether molecular typing and treatment should be carried out. There is considerable controversy over whether it should be managed as small-cell lung cancer (SCLC) or non-small-cell lung cancer (NSCLC). Therefore, in order to solve the problem of confusion in the selection of treatment regimens for CLCNEC, while also considering the therapeutic effects, this article summarizes and analyzes previous studies, fully seeks evidence, and boldly proposes new therapeutic insights: the etoposide-platinum (EP) regimen serves as the basis for adjuvant therapy; In addition, SCLC/NSCLC-CLCNEC can be distinguished based on presence of RB1 and TP53 co-mutation, and targeted therapy or NSCLC type chemotherapy including platinum + gemcitabine or taxanes (NSCLC-GEM/TAX) can be used in combination or sequentially for NSCLC-CLCNEC.https://www.frontiersin.org/articles/10.3389/fonc.2024.1449490/fullcombined large cell neuroendocrine carcinomaLCNECmolecular typingRB1 and TP53 co-mutationadjuvant chemotherapy |
| spellingShingle | Kai Kang Binfeng Li Sheng Wang Jianjian Wang Xinjun Liang Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma Frontiers in Oncology combined large cell neuroendocrine carcinoma LCNEC molecular typing RB1 and TP53 co-mutation adjuvant chemotherapy |
| title | Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma |
| title_full | Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma |
| title_fullStr | Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma |
| title_full_unstemmed | Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma |
| title_short | Clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma, a subtype of large cell neuroendocrine carcinoma |
| title_sort | clinical characteristics and treatment management of combined large cell neuroendocrine carcinoma a subtype of large cell neuroendocrine carcinoma |
| topic | combined large cell neuroendocrine carcinoma LCNEC molecular typing RB1 and TP53 co-mutation adjuvant chemotherapy |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1449490/full |
| work_keys_str_mv | AT kaikang clinicalcharacteristicsandtreatmentmanagementofcombinedlargecellneuroendocrinecarcinomaasubtypeoflargecellneuroendocrinecarcinoma AT binfengli clinicalcharacteristicsandtreatmentmanagementofcombinedlargecellneuroendocrinecarcinomaasubtypeoflargecellneuroendocrinecarcinoma AT shengwang clinicalcharacteristicsandtreatmentmanagementofcombinedlargecellneuroendocrinecarcinomaasubtypeoflargecellneuroendocrinecarcinoma AT jianjianwang clinicalcharacteristicsandtreatmentmanagementofcombinedlargecellneuroendocrinecarcinomaasubtypeoflargecellneuroendocrinecarcinoma AT xinjunliang clinicalcharacteristicsandtreatmentmanagementofcombinedlargecellneuroendocrinecarcinomaasubtypeoflargecellneuroendocrinecarcinoma |